When activated by doxorubicin, iNOS can produce micromolar amounts of NO [29], which at such high levels may act as a anti-cancer agent by impairing the aerobic mitochondrial metabolism, inhibiting the ribonucleotide reductase enzyme and directly damaging DNA via a nitrosative and oxidative stress [16,29]. The gene discussed is NOS2; the disease is cancer.